Houston pharma co. raising $139.6M through public offering, private placement


The Houston company entered the capital markets to further fund trials for its immunotherapy drug candidates.

Previous Exclusive: JPMorgan picks exec to lead Mid-Atlantic branch expansion
Next Bellwether Enterprise hires Birmingham CRE finance veteran